Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B

by Zeuzem, S., Gane, E., Liaw, Y.-F., Lim, S.G., DiBisceglie, A., Buti, M., Chutaputti, A., Rasenack, J., Hou, J., O'Brien, C., Nguyen, T.T., Jia, J., Poynard, T., Belanger, B., Bao, W., Naoumov, N.V.
Published 2016

APASL consensus statements and management algorithms for hepatitis C virus infection

by Omata, M., Kanda, T., Yu, M.-L., Yokosuka, O., Lim, S.-G., Jafri, W., Tateishi, R., Hamid, S.S., Chuang, W.-L., Chutaputti, A., Wei, L., Sollano, J., Sarin, S.K., Kao, J.-H., McCaughan, G.W.
Published 2016

Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements

by Farrell, G.C., Chan, H.L.Y., Yuen, M.F., Amarapurkar, D.N., Chutaputti, A., Fan, J.G., Hou, J.L., Han, K.H., Kao, J.H., Lim, S.G., Mohamed, R., Sollano, J., Ueno, Y., Prevent, Asai-Pacific Working Party
Published 2010

Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial

by Chan, H.L.Y., Heathcote, E.J., Marcellin, P., Lai, C.-L., Cho, M., Moon, Y.M., Chao, Y.-C., Myers, R.P., Minuk, G.Y., Jeffers, L., Sievert, W., Bzowej, N., Harb, G., Kaiser, R., Qiao, X.-J., Brown, N.A., Crawford, D., Lim, S.-G., Chutaputti, A., Poynard, T.
Published 2016